Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
| Autor: | Anastasia Ivanova, Beverly S. Mitchell, Marie Green, Anandhi R. Johri, Peter M. Voorhees, Hendrik W. van Deventer, Elizabeth G. Trehu, Dixie Lee Esseltine, Reynaldo Garcia, Fred J. Kudrik, Thomas C. Shea, Julian Adams, Don A. Gabriel, Celeste Lindley, Paul Jones, Melissa D. Hall, E. Claire Dees, Mary Jo Lehman, Robert Z. Orlowski, Tammy Allred, Susan Natoli, Jason M. Collins |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Immunology Neutropenia Pharmacology Biochemistry Polyethylene Glycols Bortezomib hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Protease Inhibitors Doxorubicin Multiple myeloma Aged Aged 80 and over Antibiotics Antineoplastic business.industry Myeloid leukemia Cell Biology Hematology Middle Aged medicine.disease Boronic Acids Regimen Treatment Outcome Hematologic Neoplasms Pyrazines Liposomes Proteasome inhibitor Female business Proteasome Inhibitors Febrile neutropenia medicine.drug |
| Zdroj: | Blood. 105:3058-3065 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg/m2 and PegLD on day 4 at 30 mg/m2 to 42 patients with advanced hematologic malignancies. Grade 3 or 4 toxicities in at least 10% of patients included thrombocytopenia, lymphopenia, neutropenia, fatigue, pneumonia, peripheral neuropathy, febrile neutropenia, and diarrhea. The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively. However, due to frequent dose reductions and delays at this level, 1.30 and 30 mg/m2 are recommended for further study. Pharmacokinetic and pharmacodynamic studies did not find significant drug interactions between these agents. Antitumor activity was seen against multiple myeloma, with 8 of 22 evaluable patients having a complete response (CR) or near-CR, including several with anthracycline-refractory disease, and another 8 having partial responses (PRs). One patient with relapsed/refractory T-cell non-Hodgkin lymphoma (NHL) achieved a CR, whereas 2 patients each with acute myeloid leukemia and B-cell NHL had PRs. Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|